Browsing Tag
NYSE American CANF
1 post
Can an A3 adenosine receptor agonist change the treatment ceiling in advanced pancreatic cancer
Can Can-Fite BioPharma Ltd.’s namodenoson change pancreatic cancer outcomes? Explore what its Phase 2a data means for investors and oncology strategy.